Abstract
Economic restraints on research and development in the pharmaceutical industry have been a favourite subject for economists, scientists and other investigators. Both static and dynamic models have been employed to measure the structure and behaviour of the industry. These researches have concentrated on specific components such as the drug approval process, effective patent life and the estimated cost of developing a new chemical entity (NCE). It would seem to be important to challenge the complex issue in broader, practical and humanistic perspectives and to assess the cumulative effect of the many external environmental research and development procedures (R &; D).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Science Indicators, National Patterns of Science and Technology Resources (various years), National Science Foundation, Washington, D.C.
United States Joint Economic Committee, Special Study on Economic Change, Productivity, The Foundation of Growth (1980); Research and Innovation, Developing a Dynamic Economy (1980); Research and Innovation, Developing a Dynamic Nation (1980), US Government Printing Office, Washington, D.C.
United States Joint Economic Committee, Special Study on Economic Change, Research and Innovation, Developing a Dynamic Nation, US Government Printing Office, Washington, D.C. (1980)
IMS Pharmaceutical Marketletter, 8 (29), 14 (1981)
Confidence in American Technology Shaken, Harris Survey no. 43, Louis Harris &; Associates, New York (1981)
Hoff, L. C., &;#x2018;Remarks before the Symposium for the 75th Anniversary of the Food Drug and Cosmetic Act&;#x2019;, sponsored by the Food Drug and Law Institute, Washington, D.C. (1981)
Prescription Industry Fact Book, Pharmaceutical Manufacturers Association, Washington D.C. (1980), pp. 22, 55, 57, 60 and 67
Fuchs, V., in Who Shall Live? Health Economics and Social Choice, Basic Books, New York (1974)
Economic Costs of FDA Regulations, Pharmaceutical Manufacturers Association, Washington, D.C. (1980)
Hansen, R., in The Pharmaceutical Development Process, Estimates of Development Costs and Times and the Effects of Proposed Regulatory Changes, Center for Research in Government Policy and Business, University of Rochester, Rochester, N.Y. (1981)
Subcommittee on Science, Research and Technology of the Committee on Science and Technology, United States House of Representatives, The Food and Drug Administration&;#x2019;s Process for Approving New Drugs, US Government Printing Office, Washington D.C. (1980)
Mathias, C. M., United States Senate, Congressional Record, 127 (14) (1981)
Statman, M., Managerial and Decision Economics, 2 (2), 61 (1981)
Virts, J., and Weston, J. F., Managerial and Decision Economics, 1 (3), 103 (1980)
Industry and Trade Commission, 1979 United States Industrial Outlook, US Department of Commerce, Washington, D.C. (1979), p. 151
Prescription Industry Fact Book, Pharmaceutical Manufacturers Association, Washington D.C. (1980), p. 29
Grabowski, H. G., Vernon, J. M., and Thomas, L. G., in Impact of Public Policy on Drug Innovation and Pricing (ed. S. Mitchell and E. Link), The American University, Washington, D.C. (1976)
FDA Drug Approval &;#x2026; A Lengthy Process that Delays the Availability of Important New Drugs, US General Accounting Office, Washington, D.C. (1981)
Manners, G. E., and Nason, H. K., Research Management, 21 (5), 8 (1978)
Drucker, P. F., Science, 204, 806 (1979)
Pharmaceutical Manufacturers Association Newsletter, 23 (26), 2 (1981)
Multiyear Authorizations for Research and Development, General Accounting Office, Gaithersbury, Md (1981)
Koenig, M. E. D., and Gans, D. J., Research Policy, 4, 330 (1981)
Meyer, F. H., and Mika, T. R., Drug and Cosmetic Industry, 128, 46 (1981)
The Pink Sheet, 43 (21) (1981)
IMS Pharmaceutical Newsletter, 8 (18) (1981)
Robert, A., Testimony before House of Representatives&;#x2019; Subcommittee on Natural Resources, Agricultural Research and Environment and Subcommittee on Investigations and Oversight, Pharmaceutical Innovation &;#x2026; Promises and Problems (1981)
Proceedings of the Thirty-Forth National Conference on the Advancement of Research, Scottsdale, Arizona, 1980
Sarett, L. H., Research Management, 17 (2), 18 (1974)
Caglarcan, E., Faust, R. E., and Schnee, J. E., in Impact of Public Policy on Drug Innovation and Pricing (ed. S. A. Mitchell and E. A. Link), The American University, Washington, D.C. (1976), p. 331
Pharmaceutical Manufacturers Association Newsletter, 23 (27), 1 (1981)
Chemical and Engineering News, 58, 60 (1980)
Parker, J. E. S., Food Drug Cosmetic Law Journal, 32, 160 (1977)
Special Report to Senior R &; D Executives, R &; D Management, SRI International, Menlo Park, Calif. (1981)
Faust, R. E., and Stevenson, R. H., Perspectives in Biology and Medicine, 21 (2), 301 (1978)
Faust, R. E., &;#x2018;Motivating the scientist in the climate for research today&;#x2019;, paper presented at the Pharm Tech Conference, Pharmaceutical Technology, Inglewood, Calif. (1981)
Griffin, R. J., American Pharmacy, 21 (6), 14 (1981)
Federal Register 46 (129), 35084 (1980)
Dewhirst, H. D., Arvey, R. D., and Brown, E. M., IEEE Transactions on Engineering Management, EM-25 (3), 58 (1978)
Lasagna, L., New England Journal of Medicine, 298, 906 (1978)
SCRIP, no. 591 (1981)
Peretz, S. M., Pharmacy International, 2 (2), 8 (1981)
IMS Pharmaceutical Marketletter, 8 (28), 12 (1981)
McMahon, G., Testimony before House of Representatives&;#x2019; Subcommittee on Natural Resources, Agricultural Research and Environment and Subcommittee on Investigations and Oversight, Pharmaceutical Innovation &;#x2026; Promises and Problems (1981)
Schweiker, R. S., paper presented at the Annual Meeting of Pharmaceutical Manufacturers Association, Boca Raton, Fla (1981)
Letter from Congressman J. H. Scheuer to President Reagan, 6 March 1981
Toffler, A., The Third Wave, William Morrow, New York (1981)
Editor information
Copyright information
© 1983 The Royal Society of Medicine
About this chapter
Cite this chapter
Faust, R.E., Harris, M.R., Lee, K.I. (1983). Economic Restraints on Research and Development in the Pharmaceutical Industry. In: L’etang, H. (eds) Regulation and Restraint in Contemporary Medicine in the UK and USA. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-06501-1_6
Download citation
DOI: https://doi.org/10.1007/978-1-349-06501-1_6
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-06503-5
Online ISBN: 978-1-349-06501-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)